Market Overview

2018 Respiratory Tract Infections Drug Development Pipeline Review - Tuberculosis, Diphtheria and Pertussis (Whooping Cough) -


The "Respiratory
Tract Infections Drug Development Pipeline Review, 2018"
has been added to's offering.

Respiratory Tract Infections Drug Development Pipeline Review, 2018
provides an overview of the pipeline landscape for respiratory tract
infections. It provides comprehensive information on the therapeutics
under development and key players involved in therapeutic development
for tuberculosis, diphtheria and pertussis (whooping cough), and
features dormant and discontinued products.

Tuberculosis, commonly known as TB, is a bacterial infection that can
spread through the lymph nodes and bloodstream to any organ in the body.
It is most often found in the lungs. The symptoms of tuberculosis range
from no symptoms (latent tuberculosis) to symptoms of active disease.
Symptoms include overall sensation of feeling unwell; cough, possibly
with bloody mucus, fatigue, shortness of breath, weight loss and pain in
the chest. There are 206 products in development for this indication.

Diphtheria is a bacterial infection that affects the membranes of the
throat and nose. If left untreated, diphtheria can cause severe damage
to kidneys, nervous system, and heart. Symptoms include sore throat and
hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal
discharge, fever and chills and malaise. Treatment includes antitoxins
and antibiotics. There are 31 products in development for this

Pertussis is a highly contagious respiratory disease. It is caused by
the bacterium Bordetella pertussis. Symptoms include runny nose, nasal
congestion, sneezing, red, watery eyes and dry cough. Treatment includes
antibiotics. There are 40 products in development for this indication.

Molecular targets acted on by products in development for respiratory
tract infections include bacterial proteins and toxins. Companies
operating in this pipeline space include Beijing Minhai Biotechnology,
Sanofi and GlaxoSmithKline.


  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage
    of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within
    this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to
    have happened in this disease area?

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

For more information about this report visit

View Comments and Join the Discussion!